Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab for ctDNA-positive biochemical relapse after radical cystectomy in muscle-invasive bladder cancer
2019-001679-36Phase 4Active
- Sponsor
- Aarhus University
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atezolizumab in transitional cell carcinoma of the bladder (TCC), sponsored by Aarhus University. Primary endpoint: Complete response after ctDNA-triggered atezolizumab. Started Jul 2019; status: active.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2019-001679-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001679-36.